Menu Search
Equities

Amerisourcebergen Corp

0HF3:LSE

Amerisourcebergen Corp

Actions
  • Price (USD)156.22
  • Today's Change0.00 / 0.00%
  • Shares traded113.00
  • 1 Year change+13.13%
  • Beta--
Data delayed at least 20 minutes, as of Feb 06 2023 16:34 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

AmerisourceBergen Corporation is a global pharmaceutical sourcing and distribution services company. The Company's U.S. Healthcare Solutions segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. This segment consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty. The Company also focuses on specialty services and a global platform of pharma manufacturer services capabilities.

  • Revenue in USD (TTM)241.81bn
  • Net income in USD1.73bn
  • Incorporated2001
  • Employees39.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ABC:NYQ since
announced		Transaction
value
PharmaLex Holding GmbHDeal completed12 Sep 202212 Sep 2022Deal completed4.90%1.28bn
Data delayed at least 15 minutes, as of Feb 06 2023 21:10 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.